BRAF Mutations in Advanced Cancers Clinical Characteristics and Outcomes 英文参考文献.docVIP

下载本文档

3
0
约5.17万字
约 13页
2017-05-11 发布于上海
举报
版权申诉

BRAF Mutations in Advanced Cancers Clinical Characteristics and Outcomes 英文参考文献.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

BRAF Mutations in Advanced Cancers Clinical Characteristics and Outcomes 英文参考文献

BRAFMutationsinAdvancedCancers:Clinical CharacteristicsandOutcomes HazemEl-Osta1,GeraldFalchook1,ApostoliaTsimberidou1,DavidHong1,AungNaing1,KevinKim2, SijinWen3,FilipJanku1,RazelleKurzrock1* 1DepartmentofInvestigationalCancerTherapeutics(PhaseIClinicalTrialsProgram),TheUniversityofTexasMDAndersonCancerCenter,Houston,Texas,UnitedStates ofAmerica,2DepartmentofMelanomaMedicalOncology,TheUniversityofTexasMDAndersonCancerCenter,Houston,Texas,UnitedStatesofAmerica,3Department ofBiostatistics,TheUniversityofTexasMDAndersonCancerCenter,Houston,Texas,UnitedStatesofAmerica Abstract Background:OncogenicBRAFmutationshavebeenfoundindiversemalignanciesandactivateRAF/MEK/ERKsignaling,a critical pathway of tumorigenesis. We examined the clinical characteristics and outcomes of patients with mutant (mut) BRAFadvancedcancerreferredtophase1clinic. Methods:Wereviewedtherecordsof80consecutivepatientswithmutBRAFadvancedmalignanciesand149withwild-type (wt)BRAF(matchedbytumortype)referredtotheClinicalCenterforTargetedTherapyandanalyzedtheiroutcome. Results:Of80patientswithmutBRAFadvancedcancer,56hadmelanoma,10colorectal,11papillarythyroid,2ovarianand 1 esophageal cancer. Mutations in codon 600 were found in 77 patients (62, V600E; 13, V600K; 1, V600R; 1, unreported). Multivariate analysis showed less soft tissue (Odds ratio (OR)=0.39, 95%CI: 0.20–0.77, P=0.007), lung (OR=0.38, 95%CI: 0.19–0.73, p=0.004) and retroperitoneal metastases (OR=0.34, 95%CI: 0.13–0.86, p=0.024) and more brain metastases (OR=2.05,95%CI:1.02–4.11,P=0.043)inpatientswithmutBRAFversuswtBRAF.ComparingtothecorrespondingwtBRAF, mutBRAFmelanomapatientshadinsignificanttrendtolongermediansurvivalfromdiagnosis(131vs.78months,p=0.14), whilemutBRAF colorectalcancer patientshadaninsignificanttrendtoshorter mediansurvivalfromdiagnosis(48vs.53 months, p=0.22). In melanoma, V600K mutations in comparison to other BRAF mutations were associated with more frequentbrain(75%vs.36.3%,p=0.02)andlungmetastases(91.6%vs.47.7%,p=0.007),